We are live on ! Find out more
JSPR icon

Jasper Therapeutics

67 hedge funds and large institutions have $56.1M invested in Jasper Therapeutics in 2025 Q1 according to their latest regulatory filings, with 13 funds opening new positions, 20 increasing their positions, 22 reducing their positions, and 30 closing their positions.

New
Increased
Maintained
Reduced
Closed

88% more call options, than puts

Call options by funds: $179K | Put options by funds: $95K

9% less repeat investments, than reductions

Existing positions increased: 20 | Existing positions reduced: 22

17.48% less ownership

Funds ownership: 104.36% → 86.88% (-17%)

21% less funds holding

Funds holding: 85 → 67 (-18)

33% less funds holding in top 10

Funds holding in top 10: 3 → 2 (-1)

57% less first-time investments, than exits

New positions opened: 13 | Existing positions closed: 30

86% less capital inflows, than outflows

Capital inflows: $10.8M | Capital outflows: $79.1M

Holders
67
Holders Change
-18
Holders Change %
-21.18%
% of All Funds
0.89%
Holding in Top 10
2
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-33.33%
% of All Funds
0.03%
New
13
Increased
20
Reduced
22
Closed
30
Calls
$179​K
Puts
$95​K
Net Calls
+$84​K
Net Calls Change
-⁠$3.97​M

JSPR Hedge Fund Activity: Q1 2025 in Review

67 of the 7,493 institutional investors tracked by Wall St. Rank reported a position in Jasper Therapeutics (JSPR) for Q1 2025, worth a combined $56.1M — down 83% from $335M a quarter earlier.

Sellers outnumbered buyers: 30 funds closed out of JSPR and 13 opened new positions — a net loss of 17 holders — while 22 trimmed existing stakes and 20 added.

The largest buyer was T. Rowe Price Investment Management, adding an estimated $4.13M. The largest seller was Braidwell, exiting entirely with an estimated $15.3M sold.

  • 67 institutional investors held Jasper Therapeutics (JSPR) as of Q1 2025, down from 85 in Q4 2024.
  • Funds reported $56.1M of Jasper Therapeutics stock for Q1 2025, down 83% quarter-over-quarter.
  • 13 funds opened new Jasper Therapeutics positions in Q1 2025 and 30 closed out, a net change of -17 holders.
  • The largest Jasper Therapeutics buyer in Q1 2025 was T. Rowe Price Investment Management, an estimated $4.13M added.
  • The largest Jasper Therapeutics seller in Q1 2025 was Braidwell, an estimated $15.3M sold.

Based on aggregated 13F filings for Q1 2025.